Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for Alzheimer's and Parkinson's diseases, announced that Founder, President and CEO Maria Maccecchini, Ph.D., will participate in two industry conferences in November. The presentations matter because they give the company a stage to detail its clinical progress and upcoming milestones to biotechnology and pharmaceutical representatives, a step that can shape partnership and financing conversations for a drug candidate aimed at halting neurodegeneration.
At U.S. Biotech Day 2026, scheduled for Nov. 16-17 in Philadelphia, Maccecchini will join a panel discussion titled "Bridging the Translational Gap: From Discovery Insights to Clinical Proof" on Nov. 16 from 9:15-9:45 a.m. ET, followed by a company presentation from 10:15-10:30 a.m. ET highlighting Annovis' clinical programs and upcoming milestones. She will also present at Pharma Partnering Summit 2026, scheduled for Nov. 19-20 in Boston. Her presentation, titled "Restoring Proteostasis in Alzheimer's and Parkinson's Diseases with Buntanetap, a Translational Inhibitor of Neurotoxic Proteins," will take place Nov. 19 from 11:25-11:55 a.m. ET. During both events, she will hold one-on-one meetings with biotechnology and pharmaceutical industry representatives to discuss the company's clinical progress and potential opportunities.
Headquartered in Malvern, Pennsylvania, Annovis Bio is developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The company maintains an online presence at www.annovisbio.com and shares updates through channels including LinkedIn, YouTube, and X.
The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. The announcement was distributed with support from MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content, which operates within the Dynamic Brand Portfolio at IBN. That network provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions.
